{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/6ac7d782f38f25c0f0591182?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?  ","description":"<p>The Lymphoma Hub was pleased to speak with Christopher P. Fox, University of Nottingham, UK. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL? </p><p><br></p><p>In this interview, Fox discusses the 3-year follow-up results from the global, randomized, phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) (n = 183) vs rituximab (R)-GemOx (n = 91) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), recently published in <em>Blood Advances</em>. He also explores outcomes across clinically relevant subgroups. </p><p><br></p><p>Intended for healthcare professionals. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. </p>","author_name":"Scientific Education Support"}